global-vaccines-2017-keynote

5 / 12

Page 15
Notes:
Ann Clin Trials Vaccines Res. 2017 | Volume 1 Issue 2
allied
academies
Global Vaccines & Vaccination Summit & B2B
November 01-02, 2017 | Toronto, Canada
Jun Dou
Southeast University, China
Colon cancer stem cell-based vaccine reduces efficiently both tumour growth and
cancer stem cell subpopulation in a mouse colon carcinoma model
Colon cancer is the most common malignant gastrointestinal
cancers that are still the most frequent cause of cancer-
related mortality in China. Colon cancer stem cells (CCSCs) are
themain reasons that result in thedrug and radiation resistance,
invasive growth, metastasis, and cancer relapse. Though many
factors involving immunosurveillance and immunosuppression
were recently validated as important for patient prognosis, a
lot of experimental immunotherapies to fight unresectable
metastatic colorectal cancer, only few cases have successfully
induced antitumor immune response against malignancies. The
goal of this work was to investigate the effects on the inhibition
of colon cancer growth by vaccination of CCSC vaccines. The
CD133+CSCs were isolated from human LOVO and mouse
CT26 cell lines by using a magnetic-activated cell sorting
system, respectively. The xenograft or syngeneic mice were
subcutaneously inoculated with the LOVO or CT26 CD133+CSC
vaccine inactivated with again and again freeze thawing
three times before the mice were challenged subcutaneously
with LOVO or CT26 cells. The inhibition tumor efficacy was
assessed by the tumorigenicity, immune efficient analysis by
flow cytometer, and enzyme-linked immunosorbent assays,
respectively. The results showed that, compared with the non-
CSC vaccine, the inhibition tumor growth efficacy of LOVO or
CT26 CSC vaccine was significantly increased in the xenograft
or syngeneic mice. Vaccination of LOVO or CT26 CD133+CSC
vaccine resulted in increasing cytotoxic activity of natural killer
cells, enhancing serum IFN-γ, and decreasing TGF-β levels in
the mice. The LOVO and CT26 CD133+CSC vaccines significantly
reduced the CSC subpopulations in the colon cancer tissues.
The data provided the first evidence that the human LOVO or
mouse CT26 CD133+CSC-based vaccine may be an attractive
therapeutic approach to excitation of anti-tumor immunity for
treatment of colon cancer.
Speaker Biography
Jun Dou now is a Director, Professor of Department of Pathogenic Biology and
Immunology, School of Medicine, Southeast University. He got his Medicine Doctor
degree (MD, PhD) in 1997 at Zhejiang University of China. He has visited the Ulm
University School of Medicine, Germany as a Visiting Scholar from Jun 1999 to Sept.
1999, and then visited the CDC, USA as a Senior Visiting Fellow from Oct. 2001 to Feb.
2004. Also, he visited the Georgia State University, USA as a Visiting Fellow from Sept.
2006 to Dec. 2006. Recently, he visited the Yale University School of Medicine, USA
twice as a Senior Visiting Fellow in 2014 and in 2015. Currently his research has focused
on the cancer stem cells (CSCs), the targeted CSCs by manipulation of nc-RNAs to treat
breast, ovarian, colon cancers, and melanoma, as well as the CSC vaccines and CSC
nanotheranostics.
e: